Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-06-09
2010-02-23
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S277100, C514S002600, C514S013800, C530S300000, C530S326000, C530S350000
Reexamination Certificate
active
07666430
ABSTRACT:
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.
REFERENCES:
patent: 5601989 (1997-02-01), Cheever et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5773230 (1998-06-01), Cheever et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6075122 (2000-06-01), Cheever et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 7060284 (2006-06-01), Kaumaya et al.
patent: 2003/0170235 (2003-09-01), Cohen
patent: 2004/0037823 (2004-02-01), Paton et al.
patent: 94/07531 (1994-04-01), None
patent: 97/38011 (1997-10-01), None
patent: 98/17797 (1998-04-01), None
patent: WO9931140 (1999-12-01), None
patent: 01/08636 (2001-02-01), None
Bernards et al., “Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector,” Proc. Natl. Acad. Sci. USA (1987), vol. 84, No. 19, pp. 6854-6858.
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science, Mar. 16, 1990, vol. 247, No. 4948, pp. 1306-1310.
Dakappagari et al., Abstract P1012, “Evaluation of synergistic Interaction Between Cytokines and Peptide Epitope Vaccines in Protection Against HER-2 Expressing Lung Metastases,” Second International and the Seventeenth American Peptide Symposium, Jun. 9-14, 2001, San Diego, California.
Dakappagari, “Evaluation of Chimeric B-Cell Epitope of HER-2: Application to Cancer Patients” Dissertation, The Ohio State University, submitted Jun. 1, 2001.
Dakappagari et al., “A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses,” The Journal of Immunology, Apr. 15, 2003, vol. 170, No. 8, pp. 4242-4253.
Dakappagari et al., “Conformational HER-2
eu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities,” J. Biol. Chem., Jan. 7, 2005, vol. 280, No. 1, pp. 54-63.
Dakappagari et al., “Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine,” Cancer Research, Jul. 15, 2000, vol. 60, pp. 3782-3789.
Dakappagari et al., Abstract P752, “Peptide Vaccine Strategies for Immunotherapy of HER-2/NEU Overexpressing Cancers,” 16th American Peptide Symposium, Jun. 26-Jul. 1, 1999, Minneapolis, Minnesota.
Disis et al., “Granulocyte-Macrophage Colony Stimulating Factor: An effective Adjuvant for Protein and Peptide-Based Vaccines,” Blood, Jul. 1, 1996, vol. 88, No. 1, pp. 202-210.
Disis et al., Immunization to Oncogenic HER-2
eu Protein with Peptide Based Vaccines, Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, New York, Mar. 1995, vol. 36, p. 251.
Disis et al., “Peptide-Based, but not whole protein, vaccines elicit immunity HER-2
eu, an Oncogenic Self-Protein,” J. of Immunol. (1996), vol. 56, pp. 3151-3158.
Frangione-Beebe et al., “Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide,” Vaccine (2001), vol. 19, pp. 1068-1081.
Gu et al., “A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas,” Cancer Res. (1988), vol. 58, No. 15, pp. 3385-3390.
Guy et al., “Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease,” Proc. Natl. Acad. Sci. USA (1992), vol. 89, pp. 10578-10582.
Harwerth et al., “Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth”, Br. J. Cancer, Dec. 1993, vol. 68, No. 6, pp. 1140-1145.
Herrera et al., “Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys,” Parasite Immunology (1997), vol. 19, pp. 161-170.
Hopp et al., “Prediction of protein antigenic determinants from amino acid sequences,” Proc. Natl. Acad. Sci. USA (1981), vol. 78, pp. 3824-3828.
Hudziak et al., “p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor,” Mol. Cell. Biol. (1989), vol. 9, pp. 1165-1172.
Jiang et al., “Evaluation of the immunogenicity of peptide and DNA constructs for HER-2
eu epitopes,” Peptides for the New Millennium, (Eds. Fields, G.B., Tam, T.P., and Barany), Kluwer Academic Publisher, Dordrecth, Netherlands, 2000, pp. 695-696.
Jiang et al., Abstract P751 “The Immunogenicity of Peptide Versus DNA Vaccine of an HER-2 CTL Epitope for Breast and Ovarian Cancers,” 16th American Peptide Symposium, Jun. 26-Jul. 1, 1999, Minneapolis, Minnesota.
Kaumaya, “HER-2
eu Cancer Vaccines: Present Status and Future,” International Journal of Peptide Research and Therapeutics (2006), vol. 12, No. 1, pp. 65-77.
Kaumaya et al., Abstract P1004, “A Combination of HER-2 Peptide Epitope Vaccines Mediate Superior Biological Effects,” Second International and the Seventeenth American Peptide Symposium, Jun. 9-14, 2001, San Diego, California.
Kaumaya et al., “De Novo' Engineering of Peptide Immunogenic and Antigenic Determinants as Potential Vaccines,” Peptides: Design, Synthesis and Biological Activity (1994), pp. 133-164.
Kaumaya et al., “Peptide Vaccines Incorporating a ‘Promiscuous’ T-cell Epitope bypass Certain Haplotype Restricted Immune Responses and Provide Broad Spectrum Immunogenicity,” Journal of Molecular Recognition (1993) vol. 6, pp. 81-94.
Kawashima et al., “Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2
eu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells,” Cancer Research, Jan. 15, 1999, vol. 59, pp. 431-435.
Kelly et al., “T-Cell, Adhesion, and B-Cell Epitopes of the Cell SurfaceStreptococcus mutansProtein Antigen I/II,” Infection and Immunity, Sep. 1995, vol. 63, No. 9, pp. 3649-3658.
Kono et al. “Identification of HER2
eu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes,” Int. J. Cancer (1998), vol. 78, pp. 202-208.
Kyngas et al., “Unreliability of the Chou-Fasman parameters in predicting protein secondary structure,” Protein Eng. (1998), vol. 11, No. 5, pp. 345-348.
Lairmore et al., “Human T-Lymphotrophic Virus Type 1 Peptides in Chimeric and Multivalent Constructs with Promiscuous T-Cell Epitopes Enhance Immunogenicity and Overcome Genetic Restriction,” Journal of Virology, Oct. 1995, vol. 69, No. 10, pp. 6077-6089.
Okugawa et al., “A novel human HER2-derived peptide homologous to the mouse K.sup.d-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphyocytes in ovarian cancer patients and healthy individuals,” Eur. J. Immunol (2000), vol. 30, pp. 3338-3346.
Pal et al. “β-Sheet propensity and its correlation with parameters based on conformation,” Acta Crystallographica Section D, Biological Crystallography, May 2000, vol.
Calfee Halter & Griswold LLP
Rawlings Stephen L
The Ohio State University
LandOfFree
Polypeptides and polynucleotides for enhancing immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides and polynucleotides for enhancing immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides and polynucleotides for enhancing immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152717